Guttmacher Institute

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications and limit minors' access to sexual and reproductive healthcare, including the HPV vaccine. A federal lawsuit challenges FDA rules allowing mifepristone to be dispensed via telehealth, with nationwide implications.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications and HPV vaccines for minors, effective July 1. The laws require in-person dispensing of abortion pills and prohibit minors under 18 from consenting to STD-related vaccinations in Iowa. A federal lawsuit challenges FDA rules allowing telehealth dispensing of mifepristone, which could impact nationwide access.

New laws in Iowa, Mississippi, and Tennessee restrict access to abortion medications like mifepristone and misoprostol and limit minors' access to the HPV vaccine. A federal lawsuit challenges FDA rules allowing telehealth dispensing of mifepristone, with nationwide implications.

A study found that 34% of women in Florida needed but did not receive reproductive healthcare services between 2024 and 2025, higher than the national average of 30%. Factors include Florida's restrictive abortion policies, lack of Medicaid expansion, and barriers like a six-week abortion ban and 24-hour waiting period.

Illinois has become a destination for abortion seekers following the overturn of Roe v. Wade, with rising demand and costs prompting increased financial aid. The Chicago Abortion Fund provided over $25 million in support in 2025, and a new public-private fund aims to assist clinics handling out-of-state patients.

The Trump administration is shifting the federal Title X program, which traditionally provided contraception access, to emphasize childbearing and family formation. The new guidelines prioritize natural methods for avoiding pregnancy and addressing infertility, potentially harming low-income and minority women reliant on the program.

A Missouri judge ruled that state laws restricting abortion violate a 2024 voter-approved constitutional amendment, striking down provisions like a 72-hour waiting period and in-person requirements for abortion pill prescriptions. The decision allows Planned Parenthood affiliates to resume prescribing abortion pills for the first time since 2018, though the state may appeal and another ballot measure is pending.

A Missouri judge ruled that several state laws restricting abortion violate a 2024 voter-approved constitutional amendment, allowing abortion until fetal viability. The decision enables Missouri Planned Parenthood affiliates to resume prescribing abortion pills for the first time since 2018, though the state plans to appeal and a future ballot measure remains pending.

The Trump administration is shifting the federal Title X program, which traditionally provided access to contraception, toward an emphasis on childbearing and family formation. The new guidelines prioritize natural methods to avoid pregnancy and promote fertility education, while prohibiting DEI efforts and linking to immigration restrictions. Health policy researchers warn this will disproportionately harm low-income and minority women reliant on Title X services.

The Trump administration is shifting the Title X federal program, which traditionally provided access to contraception, to prioritize promoting childbearing and family formation. New guidelines emphasize natural pregnancy prevention methods, fertility education, and aligning with efforts to increase the U.S. birth rate, while prohibiting DEI initiatives and restricting abortion-related services.

The Trump administration is shifting the federal Title X program, which traditionally provided contraception access, to emphasize childbearing and family formation. New guidelines prioritize natural pregnancy prevention methods, infertility treatments, and 'body literacy education,' while prohibiting DEI efforts and linking funding to reduced immigration facilitation. Critics argue the changes will disproportionately harm low-income and minority women.

The Trump administration is overhauling the federal Title X program, shifting its focus from contraception to promoting family formation and fertility awareness. The new guidelines prioritize natural methods to prevent pregnancy and address infertility, while prohibiting DEI efforts and linking funding to immigration policies. Health policy researchers warn the changes may disproportionately harm low-income and minority women.

The Trump administration is shifting the federal Title X program, which traditionally provided access to contraception, toward promoting childbearing and family formation. New guidelines prioritize natural pregnancy prevention methods and address infertility, while prohibiting DEI efforts and linking funding to anti-immigration policies. Critics argue the changes will disproportionately harm low-income and minority women reliant on Title X services.

The Trump administration is shifting the federal Title X program, which provides contraception access, to emphasize family formation and healthy pregnancies. The change prioritizes natural pregnancy methods and opposes abortion, with critics arguing it will harm low-income and minority women reliant on the program.

The Trump administration is shifting the federal Title X program, which provides reproductive health services, to prioritize promoting childbearing and family formation over contraception access. New guidelines emphasize natural pregnancy prevention methods, fertility education, and aligning with efforts to boost the U.S. birth rate, while prohibiting DEI initiatives and linking funding to immigration restrictions. Critics argue the changes will disproportionately harm low-income and minority women.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify mifepristone, an abortion medication, as a water contaminant. Environmental experts and the Center for Biological Diversity state there is no evidence of harm from mifepristone in water systems, citing a 1996 FDA statement and common drug trace amounts in water.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify mifepristone, an abortion medication, as a water contaminant. Environmental experts state there is no evidence that mifepristone in wastewater harms humans or the environment, while the request cites a 1996 FDA statement acknowledging the drug may enter the environment but noting harmful effects are 'not anticipated.'

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify the abortion medication mifepristone as a water contaminant. Environmental experts and advocacy groups state there is no evidence that mifepristone harms water systems or humans, while states have introduced legislation to test for the drug in water.

Fourteen Republican state attorneys general and 19 GOP members of Congress are urging the EPA to classify the abortion medication mifepristone as a water contaminant, citing a 1996 FDA statement. Environmental experts and the Center for Biological Diversity state there is no evidence mifepristone harms water systems or humans, while state lawmakers in seven states introduced bills addressing medication abortion's environmental impact.

Fourteen state attorneys general and 19 GOP members of Congress are urging the EPA to regulate mifepristone, an abortion medication, as a water contaminant. Environmental experts state there is no evidence that mifepristone harms water systems, while the request references a 1996 FDA statement acknowledging potential environmental entry but no anticipated harm.

American women are often misled about motherhood and abortion, with many feeling pressured into abortions due to financial and housing difficulties. A significant number of women seeking abortions already have children and would prefer to parent if their circumstances were different. Organizations like Planned Parenthood and the Human Coalition play a role in this issue.

A federal appeals court blocked the mailing of the abortion pill mifepristone under current FDA rules, requiring in-person prescriptions and likely sparking a Supreme Court battle. The 5th U.S. Circuit Court of Appeals decision restores pre-pandemic safety protocols, citing concerns over adverse event reporting and state authority, while critics warn it will limit abortion access nationwide.

A federal appeals court blocked the mailing of the abortion pill mifepristone under FDA rules, citing safety concerns and state authority, with a nationwide effect. The ruling requires in-person prescriptions for mifepristone, reversing pandemic-era changes, and sets up a potential Supreme Court challenge over abortion access.

A federal appeals court temporarily halted rules allowing teleprescribing and mailing of abortion drugs, a move backed by anti-abortion groups. The 5th Circuit's decision supports Louisiana's challenge to Biden administration policies expanding access to mifepristone, which now accounts for over 60% of abortions. Reproductive rights advocates warn this will restrict access to necessary care.